H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals (SXTP) with a Buy rating and $6 price target The firm says 60 Degrees is “flying under the radar with investors.” Tafenoquine is a differentiated, FDA approved product that is already on the market and has demonstrated “impressive” initial clinical activity in babesiosis, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals reports Q3 EPS (66c) vs. ($4.65) last year
- SXTP Upcoming Earnings Report: What to Expect?
- 60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis
- 60 Degrees announces first patient completed regimen in babesiosis trial
- 60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting